Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Consolidated Statement of Operations [Abstract]
Revenue	$ 106,000	$ 102,000
Operating expenses
Research and development	1,980,000	972,000
General and administrative	2,644,000	1,397,000
Total operating expenses	4,624,000	2,369,000
Loss from operations	(4,518,000)	(2,267,000)
Other income (expense)
Change in fair value of warrant liability	4,000	(4,690,000)
Change in fair value of Preferred B stock derivative liability	1,402,000	(7,105,000)
Other expense		(431,000)
Total other income (expense)	1,406,000	(12,226,000)
Net loss	(3,112,000)	(14,493,000)
Accretion of Series B redeemable convertible preferred stock	(1,725,000)	(338,000)
Net (loss) income attributable to common stockholders	$ (4,837,000)	$ (14,831,000)
Per share information:
Net loss per share of common stock - basic	$ (0.82)	$ (3.49)
Weighted average number of shares of common stock outstanding - basic	5,883,503	4,245,816
Net loss per share of common stock - diluted	$ (0.82)	$ (3.49)
Weighted average number of shares of common stock outstanding - diluted	5,883,503	4,245,816